Novo Nordisk–Prothena coramitug program reaches key Phase 3 milestone in ATTR cardiomyopathy
Prothena earns a $50M milestone as Novo Nordisk advances coramitug in Phase 3 for ATTR cardiomyopathy. Discover what this means for amyloid therapies.
Pharma & Biotech